- Home
- UTG vs CELC Comparison
UTG vs CELC Comparison
Compare UTG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTG
- CELC
- Stock Information
- Founded
- UTG 2003
- CELC 2011
- Country
- UTG United States
- CELC United States
- Employees
- UTG N/A
- CELC N/A
- Industry
- UTG Investment Managers
- CELC Medical Specialities
- Sector
- UTG Finance
- CELC Health Care
- Exchange
- UTG Nasdaq
- CELC Nasdaq
- Market Cap
- UTG 3.3B
- CELC 2.8B
- IPO Year
- UTG N/A
- CELC 2017
- Fundamental
- Price
- UTG $38.58
- CELC $71.27
- Analyst Decision
- UTG
- CELC Strong Buy
- Analyst Count
- UTG 0
- CELC 5
- Target Price
- UTG N/A
- CELC $69.40
- AVG Volume (30 Days)
- UTG 317.8K
- CELC 1.6M
- Earning Date
- UTG 01-01-0001
- CELC 11-13-2025
- Dividend Yield
- UTG 7.28%
- CELC N/A
- EPS Growth
- UTG N/A
- CELC N/A
- EPS
- UTG 9.86
- CELC N/A
- Revenue
- UTG $96,107,593.00
- CELC N/A
- Revenue This Year
- UTG N/A
- CELC N/A
- Revenue Next Year
- UTG N/A
- CELC N/A
- P/E Ratio
- UTG $3.20
- CELC N/A
- Revenue Growth
- UTG 8.35
- CELC N/A
- 52 Week Low
- UTG $25.26
- CELC $7.58
- 52 Week High
- UTG $35.29
- CELC $83.00
- Technical
- Relative Strength Index (RSI)
- UTG 44.29
- CELC 71.94
- Support Level
- UTG $37.06
- CELC $64.61
- Resistance Level
- UTG $41.94
- CELC $73.06
- Average True Range (ATR)
- UTG 0.81
- CELC 4.36
- MACD
- UTG -0.40
- CELC 2.44
- Stochastic Oscillator
- UTG 31.22
- CELC 69.85
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.